布地奈德辅助注射用头孢哌酮钠舒巴坦钠对2型糖尿病伴肺部感染患者疗效及肺功能与炎症介质水平的影响

Effect of Budesonide-assisted Sulbactam and Cefoperazone on Patients with Type 2 Diabetes with Pulmonary Infection and Its Effect on Lung Function and Inflammatory Factors

目的探讨2型糖尿病伴肺部感染患者应用布地奈德辅助注射用头孢哌酮钠舒巴坦钠治疗对患者疗效、肺功能、炎症介质水平的影响。方法选取2018年7月至2019年7月于苏州工业园区斜塘社区卫生服务中心治疗的2型糖尿病伴肺部感染患者60例作为研究对象,随机分为试验组与对照组,各30例。对照组采用头孢曲松钠治疗,试验组采用布地奈德辅助注射用头孢哌酮钠舒巴坦钠治疗,比较两组疗效、肺功能、炎症介质水平。结果试验组治疗有效率为93.33%,显著高于对照组的60.00%,差异有统计学意义(P<0.05);治疗后,试验组患者用力肺活量(FVC)、第一秒钟用力呼气容积(FEV1)、最大呼气峰流速(PEF)水平明显高于对照组,差异有统计学意义(P<0.05);治疗后,试验组患者细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平显著低于对照组,差异有统计学意义(P<0.05)。结论对于2型糖尿病伴肺部感染患者应用布地奈德辅助注射用头孢哌酮钠舒巴坦钠行联合治疗临床疗效显著,能有效改善患者肺功能,抑制机体炎症反应。

Objective To investigate the effect of budesonide-assisted sulbactam and cefoperazone on curative effects of patients, lung function, and inflammatory factor levels. Methods A total of sixty patients with type 2 diabetes and pulmonary infection treated in Xietang Community Health Service Center of Suzhou Industrial Park of Suzhou from July 2018 to July 2019 were selected as the research objects and were randomly divided a test group and a control group with thirty cases in each group. The control group was treated with ceftriaxone sodium and the test group was treated with budesonide-assisted Sulbactam and Cefoperazone. Curative effect, patients’ lung function, inflammatory factor levels were compared. Results The effective rate of treatment in the test group was 93.33%, which was significantly higher than the 60.00% in the control group, and the difference was statistically significant(P<0.05);after treatment, the forced vital capacity(FVC) and forced expiratory volume(FEV1) and maximum peak expiratory flow(PEF) levels were significantly higher than those of the control group, and the difference was statistically significant(P<0.05);after treatment, the test group patients’ interleukin-6(IL-6) and interleukin-8(IL-8) and tumor necrosis factor-α(TNF-α) levels were significantly lower than the control group, the difference was statistically significant(P<0.05). Conclusion The combined treatment of Budesonide-assisted Sulbactam and Cefoperazone for patients with type 2 diabetes with pulmonary infection has significant clinical effect, which can effectively improve the lung function of patients and inhibit the body’s inflammatory response.